

## INDEX OF AUTHORS

- Altmann, G., 515  
 Amick, L. D., 54  
 Argyros, T. G., 368  
  
 Baggenstoss, A. H., 298  
 Bahr, W. J., 129  
 Bauer, W., 204, 496, 522  
 Black, R. L., 101, 112  
 Blechman, W., 341  
 Bloch, K. J., 26, 112, 287  
 Bloedow, C. E., 129  
 Blumberg, B. S., 178, 421  
 Boylan, R. C., 379  
 Bunim, J. J., 112, 287  
 Burns, J. J., 475  
  
 Calhoun, D. W., 387  
 Calkins, E., 101, 204  
 Carter, P., 204  
 Castor, C. W., 140  
 Clark, G. M., 101  
 Cobb, S., 91  
 Cohen, A. S., 522  
 Corcos, J., 218  
 Crowley, G. T., Jr., 409  
 Csonka, G. W., 164  
  
 David, J. R., 112  
 Dayton, P. G., 475  
 Decker, B., 49  
 Deicher, H. R. G., 1  
 Di Fiore, J. A., 359  
 Dubois, E. L., 403  
 Duff, I. F., 64  
  
 Ehrlich, G. E., 112  
 Engel, L. L., 204  
 Epstein, W. V., 41  
  
 Fisher, E. R., 536  
 Ford, D. K., 395  
 Franklin, E. C., 16, 314  
 Freyberg, R. H., 158  
 Frohman, L. A., 64  
  
 Giles, R. B., Jr., 409  
 Goehrs, H. R., 298  
 Goldenberg, A., 515  
 Graber, W. J., III, 309  
 Graham, W., 88  
  
 Hansen, L. M., 387  
 Harris, J., 341  
 Hartung, E. F., 423  
 Harvey, J. P., Jr., 218  
  
 Heimer, R., 158  
 Henry, M., 229  
 Hershberger, L. G., 387  
 Hollander, J. L., 101, 364  
 Holley, H. L., 229  
 Holman, H. R., 1  
  
 Jacox, R. F., 170  
 Jeanloz, R. W., 233  
 Johns, R. J., 328  
 Johnson, P. C., 129  
  
 Katz, Y. J., 403  
 Kunkel, H. G., 1  
 Kyriakopoulos, A. A., 129  
  
 Lee, R. C., 41  
 Lerner, E. M., II, 26  
  
 McGuckin, W. F., 49  
 McKenzie, B. F., 49  
 MacLachlan, M. J., 152  
 Mainland, D., 101  
 Malm, O., 341  
 Martel, W., 76, 546  
 Mikkelsen, W. M., 101  
 Mitchell, D. M., 204  
 Muller, A. F., 496  
  
 Oglesby, R. B., 287  
  
 Page, J. W., 546  
 Plotz, C. M., 515  
  
 Ragan, C., 101  
 Reece, W. E., 112  
 Rhineland, F. W., 561  
 Rodnan, G. P., 152, 195, 536  
 Ropes, M. W., 496  
  
 Sanford, J. P., 309  
 Sayers, G., 350  
 Seegmiller, J. E., 475  
 Seidenfeld, M. A., 557  
 Ship, I. I., 287  
 Short, C. L., 101  
 Silberberg, D. H., 64  
 Silverstein, E., 485  
 Singer, J. M., 515  
 Slocumb, C. H., 49, 298  
 Smith, J. E., 409  
 Sokoloff, L., 186, 379, 485  
 Solomon, N., 350  
 Steinbrocker, O., 368  
 Stuart, F. S., 229

- Tristan, T. M., 170  
 Vaughan, J. H., 341  
 Ward, J., 522  
 West, K. M., 129  
 Williams, R. R., Jr., 26  
 Wohl, M. J., 287  
 Wright, V., 328  
 Wyngaarden, J. B., 414  
 Young, N., 341  
 Ziff, M., 309  
 Zvaifler, N. J., 76  
 Zuelzer, W. W., 884

## INDEX OF SUBJECTS

- ACTH. *See* Steroids  
 Adrenal gland  
   after steroid therapy in rheumatoid arthritis, 240  
   cortical androgen secretion, Nilevar affecting, 341-347  
   dexamethasone affecting potencies of, 115, 135  
   insufficiency after abrupt cessation of cortisone, 204-216  
 Agar, double diffusion technics in, 16-24  
 Agglutination reactions  
   latex. *See* Latex agglutination of nonrheumatoid sera, 277  
   sheep cell. *See* Sheep cells, agglutination tests  
   tests for rheumatoid factor, 431  
   *See also* Hemagglutination  
 Albumin, serum, absorption from knee, 152-157  
 Alkaptonuria, 238, 359-363  
 American Rheumatism Association  
   Alexander case, decision in, 97  
   Amsterdam Conference on social aspects of arthritis, 98  
   annual meeting (1960), proceedings of, 429-471  
   annual meeting (1961), schedule for, 567  
   annual meeting for business, 376  
   award to Dr. Lancefield, 472  
   Australian Association, 378  
   Bunim to give Heberden oration, 285  
   courses  
     in Jersey City, 472  
     in Seattle, 472  
     at University of Michigan, 98  
   Empire Rheumatism Council symposium, 99  
   European League Against Rheumatism, Istanbul Meeting, 99  
   fraudulent ads, report of, 472  
   future meetings, 377  
   Hartung installed as President, 284  
   International Congress, in Rome, 193, 377, 567-568  
   new members, admissions for, 378  
   Primer on Rheumatic Diseases, 98  
   publications available, 193  
   Rheumatism Review Committee, 285  
   Rome travel grants, 567  
   Seventh Interim Scientific Session, 285, 377, 471  
   Sixth Interim Scientific Session, 97, 238-284  
 Amines, effects on connective tissue, 447  
 Amnion tissue culture, and PPLO isolation, 395-401  
 Anemia, of rheumatoid arthritis, 460  
 Antibodies  
   antinuclear, in experimental animals, 439  
   response pattern in rheumatic disease, 455  
 Antigen-antibody complexes  
   absorbing rheumatoid factor preparations, 439  
   and gamma globulin, 17  
   and hypersensitivity lesions, 470  
 Antigens  
   cytoplasmic, in diseases, 1-13  
   factors in rheumatoid arthritis, 158  
   joint, in attempted experimental lupus erythematosus, 403-407  
 Anturan therapy, 374, 482  
 Aorta, mucopolysaccharides of, 452  
 Arabinose, entrance into joints, 504  
 Arthritis  
   feet in differential diagnosis of, 435  
   history of, 421-422  
   research, creativity in, 423-428  
   synovial fluid studies, 364-367  
   ulcerative colitis with, 282  
   *See also specific types of arthritis*  
 Arthrograms, in leg cysts with rheumatoid arthritis, 218-228  
 Aspirations, joint, technics of, 364-365  
 Atlanto-axial subluxation, in rheumatoid arthritis, 446, 546-555  
 Atrophy, muscular, in rheumatoid arthritis, electrodiagnosis of, 54-61  
 Baker's cyst, with rheumatoid arthritis, 218-228  
 Basophil count, in rheumatoid arthritis, 434  
 Bentonite flocculation test  
   in experimental arthritis, 26-39  
   in rheumatoid arthritis, juvenile, 469  
   in Sjogren's syndrome, 288  
 Biliary cirrhosis, anti-cytoplasmic factors in sera of patients with, 1-13  
 Blood group substances, 233

- Bone necrosis, aseptic  
 hip deterioration and femoral head collapse in, 463  
 in lupus erythematosus, 442
- Book reviews  
 Arthritis, General Principles, Physical Medicine, Rehabilitation (*Lowman, ed.*), 473  
 Arthritis: Medical Treatment and Home Care (*Bland*), 570  
 Gouty Arthritis and Gout (*Weiss & Segaloff*), 473  
 Lymphocytes and Mast Cells (*Kelsall & Crabb*), 474  
 Re-education of the Injured Shoulder (*Brookes*), 99
- Breast carcinoma, metastatic to foot bones, 170-176
- Butazolidin. *See* Phenylbutazone
- Calcium balance  
 after cortisone therapy cessation, 212  
 in rheumatoid disease, Nilevar affecting, 341-347
- Carbohydrates  
 dexamethasone affecting metabolism, 119-121  
 of synovial fluid, 409-413
- Carcinoma  
 breast, metastatic to foot bones, 170-176  
 prostate, rheumatic symptoms with, 449  
 Cardiac lesions, in rheumatoid arthritis, 298-307
- Cartilage  
 bovine nasal, 246  
 chondroitin sulfate in, 409  
 matrix depletion in hypervitaminosis A, 253  
 papain affecting, 455
- Cataracts, after corticosteroid therapy, 432
- Cells  
 anti-cytoplasmic factors in sera of patients with diseases, 1-13  
 rheumatoid factor in, 262  
 synovial, 142-146  
 chromosomes in, 436  
 cultures of, 267  
 staining of, 448  
*See also specific cells*
- Cervical vertebra. *See* Spine
- Chitin, 236
- Chloride excretion, after dexamethasone, 132-135
- Chloroquine therapy, in rheumatoid arthritis, 470
- Chondritis, relapsing, 278
- Chondroitin sulfate, 234  
 in aorta, 452  
 in cartilage, 409  
 in latex fixation test, 158-163
- Chromium, radioactive, clearance from knee, 195-203
- Chromosomes, in cells from synovial tissue, 436
- Cirrhosis, biliary, anti-cytoplasmic factors in sera of patients with, 1-13
- Cold  
 cryoglobulins in lupus erythematosus, 449  
 experimental injury, and fibrinoid necrosis, 453
- Colitis, ulcerative  
 arthritis with, 282  
 spondylitis with, 76-86
- Collagen  
 dermal, changes in scleroderma, 541  
 fibers, synovial, 146  
 lysine in mineralization of, 250  
 synthesis by fibroblasts in tissue culture, 267  
 synthetic activity, and RNA production, 252
- Complement fixation reactions, and cytoplasmic cellular constituents in disease, 1-13
- Connective tissue  
 cells, synovial, unclassified, 145  
 development in polyvinyl sponges, 433  
 disorders, stiffness in, 255  
 growing, nucleic acids in, 252  
 hexamine concentrations in, 409-413  
 metabolism, therapeutic agents affecting, 434  
 papain affecting, 440  
 proliferation, serotonin affecting, 447  
 in Whipple's disease, 438
- Correspondence, 100, 568-570
- Corticosteroids. *See* Steroids
- Cryoglobulins, in lupus erythematosus, 449
- Cysts, in leg, with rheumatoid arthritis, 218-228
- Denervation, sympathetic, in intractable pain, 450
- Dermatan sulfate, 235
- Dermatomyositis  
 muscle fiber degeneration in, 60  
 vascular lesions in, 379-385
- Dermotoidin sulfate, 234
- Desoxyribonuclease (DNase), in tissue preparations, and complement fixation titer, 1-13
- Desoxyribonucleic acid (DNA)  
 antibodies against, in lupus erythematosus, 403-407  
 clot inhibition by L.E. serum, 256  
 and experimental lupus erythematosus, 439  
 of growing connective tissue, 252  
 and NP-E hemagglutination, 43, 45  
 serum reactant to, in lupus erythematosus, 458
- Dexamethasone therapy, 112-126  
 adrenal suppressive potencies of, 115, 135  
 cataracts after, 432  
 eosinopenic potency of, 129-138  
 hormonal effects of, 114-122, 129  
 hyperglycemic effect of, 119, 129-138  
 peptic ulcer after, 442  
 physiologic effects of, 129-138  
 side effects of, 122-125  
 water and electrolyte excretion after, 132-135
- Dextran, interaction with rheumatoid factor, 443

- Diabetes
  - feet changes in, 436
  - and stiff-man syndrome, 231
- Diabetogenic properties of dexamethasone, 119
- Diagnostic criteria, 91-95
- Differential diagnosis of arthritis, feet in, 435
- Dinitrophenol, effects on entrance of glucose into joints, 506
- Elastic fibers, synovial, 146
- Electrodiagnosis of muscle atrophy in arthritis, 54-61
- Endothelial cells, synovial, 145
- Erosions, cervical vertebral, in rheumatoid arthritis, 546-555
- Erythema nodosum, acute phase reactants in, 49-52
- Erythrocytes, labeled, clearance from knee joint, 195-203
- Experimental arthritis, 186-190
  - bentonite flocculation test in, 26-39
  - DNA and joint antigens in, 403-407
  - from Freund's adjuvants, 485-494
  - immunization to, 387-393
  - pathogenesis of, 463
- Experimental hemarthrosis, 195-203
- Experimental lupus erythematosus, 259, 403-407, 439
- Experimental obesity and osteoarthritis, 465
- Family studies
  - in lupus erythematosus, 244, 445, 460
  - in rheumatoid arthritis, 178-182, 437
  - See also* Twins
- Fasting, effects on uric acid excretion, 280
- Feet
  - breast carcinoma metastases in, 170-176
  - in differential diagnosis of arthritis, 435
- Femoral head, collapse of, 463
- Fibrinoid necrosis of blood vessels and connective tissue, 453
- Fibroblasts, and mucopolysaccharide synthesis, 267
- Flexin, uricosuric effects of, 482
- Fluorescent technics
  - antibody studies in Sjogren's syndrome, 289
  - antiglobulin studies of serum reactant to DNA in lupus erythematosus, 458
  - antisera identifying streptococci, 261
  - staining of rheumatoid leukocytes, 450
- Fructose, entrance into joints, 501
- G-27202, therapy with, 374
- G-28315, therapy with, 374
- G-29701, uricosuric effect of, 281, 475-483
- Galactosamine, in synovial fluid, 409-413
- Galactose, entrance into joints, 501
- Gamma globulins
  - absorption from knee, 152-157
  - aggregated, 268
  - and antigen-antibody complexes, 439
  - dye-labeled, and rheumatoid sera, precipitates between, 272
  - precipitin for, 270
  - reaction with rheumatoid leukocytes, 450
  - and experimental lupus erythematosus, 439
  - inhibiting sheep-cell agglutination reaction, 314-326
  - in latex fixation test, 158
  - and latex particles, 273, 515-520
  - and NP-E hemagglutination test, 43
  - in relatives of patients with lupus erythematosus, 244
  - in rheumatoid arthritis, 264
  - rheumatoid arthritis with hypogammaglobulinemia, 274
  - and rheumatoid factors, reaction between, 16-24, 444
  - and serologic reactions in diseases, 1-13
- Genetics
  - and alkaptonuria, 238
  - and rheumatoid arthritis, 178-184, 437, 446
- See also* Family studies
- Genital tracts, PPLO isolation from, 395-401
- Glucosamine, in synovial fluid, 409-413
- Glucose
  - entrance into joints, 496-513
  - in experimental production of L.E.-like disease, 259
  - tolerance in stiff-man syndrome, 231
  - utilization, dexamethasone affecting, 119-121, 136
- Glycine, and uric acid excretion in gout, 448
- Glycogen deposition, dexamethasone affecting, 119
- Glycopeptide, 236
- Glycopolypeptides, 233
- Glycoproteins, 233, 236
  - in rheumatic diseases, 49-52
- Gm serum in rheumatoid arthritis, 465
- Gold therapy, affecting connective tissue metabolism, 434
- Genococcal arthritis, sex incidence of, 309-312
- Gout
  - hyperuricemia in, 414-419
  - kidney in, 466
  - in medical art, 461
  - trimethylcolchicine acid in, 469
  - urate crystals in synovial fluid, 454
  - uric acid excretion in, glycine affecting, 448
- Ground substance, synovial, 146
- Hand, rheumatoid, surgery of, 437
- Hartung, Edward, 284, 424
- Heart lesions in rheumatoid arthritis, 298-307
- Heart-lung preparation, rat, 350-358
- Hemagglutination studies
  - of L.E. cell formation, 257
  - nucleoprotein extract, 41-47
- Hemarthrosis, experimental, 195-203
- Hemophilia, hemarthrosis with, 195-203
- Heparin, 234
  - in latex fixation test, 158-163
- Heparitan, in aorta, 452
- Hepatitis, lupoid, sera of patients with, 2

- Hereditary conditions. *See* Genetics
- Hexamincobaltic chloride, and DNA clot formation, 256
- Hexosamine  
in aorta, 452  
in rheumatic diseases, 49-52  
in synovial fluid, 409-413
- Hexose, protein-bound, in rheumatic diseases, 49-52
- Hip joint, deterioration of, 463
- Histamine, effects on connective tissue, 448
- Histone, reacting with DNA, 256
- History of arthritis and rheumatism, 421-422
- Homogentisic acid oxidase deficiency, 359-363
- Human fraction II, aggregated, 268, 270, 272, 439, 450
- Hyaluronate  
in aorta, 452  
in synovial fluid, 247
- Hyaluronic acid, 235, 236  
in latex fixation test, 158  
in synovial fluid, 409, 459  
and tissue permeability, 458
- Hyaluronidase, effects on clearance of radioactivity, 195-203
- Hydralazine  
effects on connective tissue, 448  
lupus erythematosus after, 464
- Hydrocortisone  
effects on clearance of radioactivity, 195-203  
physiologic effects of, 129-138
- Hydroxyapatite, on collagen fibers, 250
- Hypertensives, heat stable rheumatoid factor in, 435
- Hypospray technic for intra-articular injection, 430
- Immobilization  
effects on clearance of radioactivity, 195-203  
splinting, in rheumatoid arthritis, 462
- Immunization to arthritis, 387-393
- Immunological reactions, in Sjogren's syndrome, 433
- Infectious arthritis, acute phase reactants in, 49-52
- Inflammation, measurements of, 49-52
- Injections, intra-articular, hypospray technic for, 430
- Intimal cells, synovial, 142-145
- Iproniazid, effects on connective tissue, 448
- Iron, radioactive, clearance from knee, 195-203
- Isoniazid, effects on connective tissue, 448
- Joints  
glucose and sugars in, 496-513  
in hyperparathyroidism, 471  
injections in, hypospray technic for, 430  
in sarcoidosis, 453  
stiffness in. *See* Stiffness
- Keratosulfate, 236
- Kidney  
in gout, 466  
in lupus erythematosus, 461
- Knee  
cysts with rheumatoid arthritis, 218-228  
osteoarthritis of, 561-563, 564-566  
radiochromium and radioiron clearance from, 195-203  
serum albumin and gamma globulin absorption from, 152-157
- Latex agglutination  
patterns of, 435  
in serum and synovial fluid, 447
- Latex fixation test  
in juvenile rheumatoid arthritis, 469  
in leprosy, 436  
mucopolysaccharides in, 158-163  
in rheumatoid arthritis, inhibitors and stabilizers of, 432
- Latex particles  
binding protein, 273  
sensitized by gamma globulin, 515-520
- L.E. cell formation  
extracellular material in, 466  
factors in, 1, 41-47  
hemagglutination studies, 257
- Leg  
cysts, with rheumatoid arthritis, 218-228  
ulcers, in rheumatoid arthritis, therapy of, 430
- Leprosy, latex fixation test in, 436
- Leukemia, with spondylitis treated with x-ray, 64-74
- Leukocytes  
basophil, in rheumatoid arthritis, 434  
L.E. serum affecting, 444  
rheumatoid, reaction with aggregated gamma globulin, 450
- Lupus erythematosus  
acute phase reactants in, 49-52  
anti-cytoplasmic factors in sera of patients with, 1-13  
attempts to produce, 259, 403-407  
bone necrosis in, avascular, 442  
cryoglobulins in, 449  
and DNA clot inhibition, 256  
drug-induced, 464  
experimental, antinuclear antibodies in, 439  
familial occurrence of, 460  
hypergammaglobulinemia in relatives of patients with, 244  
inhibition of lupus factor, 43  
para-toluene sulfonic acid test in, 467  
relatives of patients with, 439, 445, 460  
renal lesion in, 461  
serum affecting leukocytes, 444  
serum reactant to DNA in, 458  
skin test in, 431  
*See also* L.E. cell formation
- Lymphosarcoma, Murphy rat, arthritogenic activity of exudate, 387-393
- Lysine, in mineralization of collagen, 250
- Magnesium excretion, after dexamethasone, 135
- Marsilid, effects on connective tissue, 448
- Mast cells  
blood, in rheumatoid arthritis, 434

- synovial, 145
- Measles, and arthritis, 451
- Medrol, evaluation of, 284
- Mesothelioma, pleural, arthropathy with, 443
- Metastatic bone lesions, 170-176
- Mineral metabolism, in rheumatoid disease, Nilevar affecting, 341-347
- Mineralization of collagen, lysine in, 250
- Mucin, 233
- Mucoids, 233
- Mucopolysaccharides
  - of aorta, 452
  - in latex fixation test, 158-163
  - nomenclature of, 233-237
  - in sclerodermatous skin, 541
  - synthesis by fibroblasts in tissue culture, 267
- Mucopolyuronides, 233
- Mucoproteins, 233
- Muscles
  - atrophy in rheumatoid arthritis, electro-diagnosis of, 54-61
  - dermatomyositis, 60, 379-385
  - polymyositis, 441
  - rigidity in stiff-man syndrome, 229-231
- Mycoplasmal polyarthritis, and tumor regression, 260
- Nasal cartilage, bovine, 246
- Necrosis
  - bone
    - hip deterioration and femoral head collapse in, 463
    - in lupus erythematosus, 442
  - fibrinoid, of blood vessels and connective tissue, 453
- Nerves, sympathetic denervation in intractable pain, 450
- Nilevar, effects on metabolism in rheumatoid disease, 341-347
- Nitrogen balance
  - after cortisone therapy cessation, 212
  - in rheumatoid disease, Nilevar affecting, 341-347
- Nonrheumatoid sera, properties of, 277
- Nucleic acids, of growing connective tissue, 252
- Nucleoprotein extract, hemagglutination test, 41-47
- Obesity, experimental, and osteoarthritis, 465
- Ochronosis, 359-363
  - pathogenesis of, 457
- Osteoarthritis
  - acute phase reactants in, 49-52
  - and experimental obesity, 465
  - of knee, 561-563, 564-566
- Osteoarthropathy, hypertrophic and intrathoracic disease, 443
  - pulmonary, acute phase reactants in, 49-52
- Osteochondritis, spinal in twins, with spondylitis, 444
- Oxyphenbutazone, keto analog of, uricosuric effect of, 281, 475-483
- Pain, intractable, sympathetic denervation in, 450
- Papain
  - effects on cartilage, 455
  - effects on connective tissue, 440
- Parathyroid disorders, joints in, 471
- Para-toluene sulfonic acid test, evaluation of, 467
- Peptic ulcer, after corticosteroids, 442
- Periarteritis nodosa, 456
- Periarthritis, experimental production of, 485-494
- Pharyngitis, streptococcal, and rheumatic fever, 464
- Phenylbutazone therapy, 368-374
  - synovial tissue after, 445
- Phloridzin, affecting entrance of glucose into joints, 506
- Phosphorus balance
  - after cortisone therapy cessation, 212
  - in rheumatoid disease, Nilevar affecting, 341-347
- Pituitary
  - dexamethasone affecting activity of, 115
  - from polyarteritic animals, transplants of, 239
  - function after steroid therapy in rheumatoid arthritis, 240
- Platelets, redox activity of, on addition of serotonin, 452
- Pleural mesothelioma, arthropathy with, 443
- Pleuropneumonia-like organisms (PPLO)
  - in experimental arthritis, 463
  - neutralization of, 387-393
  - in polyarthritis, 260
  - in urethritis with arthritis, 395-401
- Polyarteritis nodosa, induction of, 239
- Polyarthritis, mycoplasmal, and tumor regression, 260
- Polychondritis, relapsing, 278
- Polymyositis, 441
  - electromyography in, 60
- Polysaccharides, 233
  - interaction with rheumatoid factor, 443
- Popliteal cysts, with rheumatoid arthritis, 218-228
- Potassium excretion, after dexamethasone, 135
- Precipitin reaction, between rheumatoid factors and gamma globulin, 16-24
- Prednisolone and prednisone
  - cataracts after, 432
  - peptic ulcer after, 442
  - physiologic effects of, 129-138
- Pressure gradient therapy of leg ulcers in rheumatoid arthritis, 430
- Prostate carcinoma, rheumatic symptoms with, 449
- Proteins
  - cryoglobulins in lupus erythematosus, 449
  - glycoproteins, 49-52, 233, 236
  - metabolism in rheumatoid disease, Nilevar affecting, 341-347
- serum
  - permeability of synovium to, 152-157
  - in rheumatic diseases, 49-52
  - and serologic reactions in diseases, 1-13
  - in Sjogren's syndrome, 288



- in synovial fluid, and hyaluronic acid, 459
- See also Gamma globulin
- Psoriatic arthritis, 429
  - feet in, 435
- Psychological factors in rheumatoid arthritis, 456
- Radiation therapy, in rheumatoid spondylitis, leukemia after, 64-74
- Radiology
  - of Reiter's syndrome, 469
  - of spondylitis and rheumatoid arthritis, 441
- Reactants, acute phase, in rheumatic diseases, 49-52
- Recurrent attacks, in Reiter's disease, 164-169
- Redox activity of platelets, on addition of serotonin, 452
- Rehabilitation centers, selection of, 557-560
- Reiter's syndrome
  - acute phase reactants in, 49-52
  - cutaneous signs of, 469
  - diagnosis of, 312
  - PPLO in, 395-401
  - radiology of, 469
  - recurrent attacks in, 164-169
- Research in arthritis, creativity in, 423-428
- Reticular fibers, synovial, 147
- Rheumatic diseases
  - acute phase reactants in, 49-52
  - antibody response in, 455
- Rheumatic fever
  - case registry in Dade County, 462
  - chronic, 466
  - and streptococcal pharyngitis, 464
- Rheumatic symptoms, with carcinoma of prostate, 449
- Rheumatism, history of, 421-422
- Rheumatoid arthritis
  - acute phase reactants in, 49-52
  - anemia of, 460
  - anti-cytoplasmic factors in sera of patients with, 1-13
  - antigenic factors in, 158
  - basophil leukocytes in, 434
  - cardiac lesions in, 298-307
  - cataracts after corticosteroid therapy, 432
  - cervical spine lesions in, 446, 454, 546-555
  - chloroquine therapy, 470
  - cortisone therapy, abrupt cessation of, 204-216
  - dexamethasone in, 112-126
  - experimental, 403-407
  - feet in, 435
  - and fibrinoid necrosis, 453
  - gamma globulin complexes in sera, 264
  - and genetics, 178-184
  - Gm serum in, 465
  - hypogammaglobulinemia with, 274
  - juvenile, serological tests in, 469
  - latex agglutination in serum and synovial fluid, 447
  - latex fixation test for, inhibitor and stabilizer of, 432
  - leg cysts with, 218-228
  - leg ulcers with, therapy of, 430
  - long-term steroid therapy, 451
  - muscle atrophy in, electrodiagnosis of, 54-61
  - Nilevar affecting metabolism in, 431-437
  - occasional attacks of, 438
  - pituitary-adrenal function after steroid therapy, 240
  - psychosocial factors in, 456
  - roentgen features of, 441
  - and rubella arthritis, 451
  - sensitized sheep-cell agglutination reaction in, 266
  - splinting in, 462
  - sugars entering joints in, 506
  - therapeutic evaluation in, 101-110, 284
  - thermolabile inhibition in, 462
  - transmission of, 437
  - visceral lesions in, 242
- Rheumatoid factor
  - absorption of preparations, 439
  - agglutination tests for, 431
  - binding to cellular elements, 450
  - cellular origin of, 262
  - dextran interaction with, 443
  - and gamma globulin, reaction between, 16-24, 444
  - hereditary factors in, 446
  - in hypogammaglobulinemia with rheumatoid arthritis, 274
  - inhibition of activity, 43
  - and latex agglutination, 435
  - and particulate carrier reactions, 515-520
- Rheumatoid hand, surgery of, 437
- Rheumatoid heart disease, 298-307
- Rheumatoid serologic reactions in animals, 26-39
- Rheumatoid spondylitis. See Spondylitis, ankylosing
- Ribonuclease (RNase), in tissue preparations, and complement fixation titer, 1-13
- Ribonucleic acid (RNA), production in growing connective tissue, 252
- Roentgen studies. See Radiology
- Rubella arthritis, 451
- Salicylates, affecting connective tissue metabolism, 434
- Sarcoidosis, joint involvement in, 453
- Scleroderma
  - in progressive systemic sclerosis, 536-545
  - skin mobility in, 429
- Sclerosis, progressive systemic, cutaneous lesion of, 536-545
- Scorbutic animal collagen synthetic activity in, 252
- Seromucoid, in rheumatic diseases, 49-52
- Serotonin
  - and connective tissue proliferation, 447
  - and redox activity of platelets, 452
- Sheep cells
  - agglutination tests, 26-39
  - in Sjogren's syndrome, 288
  - stabilizers and inhibitors in, 266, 314-326
  - tannic acid-treated, coating of, 42
- Sialic acids, 250
  - in rheumatic diseases, 49-52

- Sjögren's syndrome  
 anti-cytoplasmic factors in sera of patients with, 1-13  
 serologic reactions in, 283, 287-295  
 vascular lesions and immunological reactions in, 433
- Skin  
 dermatomyositis, 60, 379-385  
 mobility in scleroderma, 429  
 in progressive systemic sclerosis, 536-545  
 in Reiter's syndrome, 469  
 test, in lupus erythematosus, 431
- Social factors in rheumatoid arthritis, 456
- Sodium balance  
 after cortisone therapy cessation, 209  
 after dexamethasone, 132-135
- Spine  
 lesions in rheumatoid arthritis and ankylosing spondylitis, 446, 454, 546-555  
 osteochondritis in twins, with ankylosing spondylitis, 444
- Splinting, in rheumatoid arthritis, 462
- Spondylitis, ankylosing  
 cervical spine lesions in, 446, 454, 546-555  
 early characteristics of, 459  
 leukemia after x-ray therapy in, 64-74  
 roentgen features of, 441  
 as separate entity, 88-90  
 in twins, with spinal osteochondritis, 444  
 ulcerative colitis with, 76-86, 282  
 visceral lesions in, 242
- Sponges, polyvinyl, connective tissue development in, 433
- Steroid excretion, after cortisone therapy cessation, 212-213
- Steroids  
 abrupt cessation of, 204-216  
 cataracts after, 432  
 effects on blood vessels, 457  
 effects on connective tissue metabolism, 434  
 long-term, study of, 451  
 peptic ulcer after, 442  
 physiologic effects of, 129-138  
 pituitary-adrenal function after, 240
- Stiff-man syndrome, 229-231
- Stiffness  
 in connective tissue disorders, 255  
 measurement of, 328-338
- Streptobacillus moniliformis, joint lesions from, 26-39
- Streptococcal pharyngitis, and rheumatic fever, 464
- Streptococci, fluorescent antiserum identifying, 261
- Sulfinpyrazone, uricosuric effects of, 482
- Suppurative arthritis, acute, 522-534
- Surgery  
 of rheumatoid hand, 437  
 sympathetic denervation in intractable pain, 450
- Sympathetic denervation, in intractable pain, 450
- Synovial cell cultures, 267
- Synovial fluid  
 in arthritis with urethritis, 395-401  
 carbohydrates of, 409-413  
 cell count in, 365  
 examination, in arthritis, 364-367  
 glucose concentration in, 496  
 gouty, urate crystals in, 454  
 hyaluronate isolation from, 247  
 latex agglutination in, 447  
 protein in, and hyaluronic acid, 459
- Synovial membrane, lining cells of, staining of, 448
- Synovial tissue  
 cells from, chromosomes in, 436  
 cellular components, 142-146  
 fibrillar components, 146-148  
 ground substance, 146  
 microscopic structure of, 140-150  
 phenylbutazone affecting, 445  
 and popliteal space masses, 218-228
- Synovium  
 inflammation, clinical index of, 49-52  
 permeability to protein, 152-157
- Therapy of rheumatoid arthritis, evaluation of, 101-110, 284
- Thiocyanate, entrance into joints, 498, 501
- Thoracic disease, and hypertrophic osteoarthropathy, 443
- Thrombophlebitis of leg veins, differential diagnosis of, 218-228
- Thymus antigen, in attempted experimental lupus erythematosus, 403-407, 439
- Thyroid function, dexamethasone affecting, 115-119
- Traumatic arthritis, acute phase reactants in, 49-52
- Triamcinolone, peptic ulcer after, 442
- Trimethadione, lupus erythematosus after, 464
- Trimethylcolchicinic acid (TMCA), in gout, 469
- Trypsin, in tissue preparations, and complement fixation titer, 1-13
- Tumor regression, and mycoplasmal polyarthritis, 260
- Twins  
 rheumatoid arthritis, 182-183  
 spinal osteochondritis in, with ankylosing spondylitis, 444
- Ulcers  
 leg, in rheumatoid arthritis, therapy of, 430  
 peptic, after corticosteroids, 442
- UML 491, effects on connective tissue, 448
- Urate crystals, in gouty synovial fluid, 454
- Urethritis  
 arthritis with, PPLO in, 395-401  
 and Reiter's disease, 164-169
- Uric acid  
 after glycine in gout, 448  
 fasting affecting excretion, 280  
 hyperuricemia in Filipinos, 440  
 hyperuricemia in gout, 414-419
- Uricosuric effect of keto analogue of oxyphenbutazone, 281, 475-483



- Vascular conditions
  - in dermatomyositis, 379-385
  - in experimental cold injury and rheumatoid disease, 453
  - periarteritis nodosa, 456
  - in Sjogren's syndrome, 433
  - steroid therapy affecting blood vessels, 457
- Venereal urethritis with arthritis, 309-312, 395-401
- Vertebra. *See* Spine
- Vitamin A, and cartilage matrix depletion, 523
- Wassermann reaction, false positive, serum factors in, 2
- Water excretion, after dexamethasone, 132-135
- Whipple's disease, connective tissue in, 438
- X-rays. *See* Radiation
- Xylose, entrance into joints, 503
- Zoxazolamine, uricosuric effects of, 482